Viemed shareholders reelect all eight directors; Nitin Kaushal receives only 56.33% support

VIEMED HEALTHCARE, INC.

All eight director nominees elected at June 13 annual meeting; Nitin Kaushal had 43.67% votes withheld.
Ernst & Young LLP ratified as auditor for FY 2023 with 99.69% of votes cast in favor.
Meeting turnout: 27,309,147 shares represented (71.33% of outstanding).
Broker non-votes of 3,957,661 for director elections; no broker non-votes on auditor ratification.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VIEMED HEALTHCARE, INC. shareholders approved Election of eight directors to serve until the close of the next annual meeting of shareholders or until their successors are elected. at the 2023-06-13 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-13

Exact text from the filing

Each of the eight nominees listed below were elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

VIEMED HEALTHCARE, INC. shareholders approved Appointment of Ernst & Young LLP as auditors of the Company for the fiscal year ending December 31, 2023 and authorization of the Board to fix their remuneration. at the 2023-06-13 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-13

Exact text from the filing

The shareholders approved the appointment of Ernst & Young LLP as auditors of the Company for the fiscal year ending December 31, 2023 and the authorization of the Board to fix their remuneration.

View on SEC.gov

Browse all shareholder votes →

VIEMED HEALTHCARE, INC. filing history →

Source: SEC EDGAR

accession 0001729149-23-000091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.